CN102719401B - Hla-a0201限制性抗mage抗原特异性ctl的制备方法 - Google Patents
Hla-a0201限制性抗mage抗原特异性ctl的制备方法 Download PDFInfo
- Publication number
- CN102719401B CN102719401B CN201210231840.XA CN201210231840A CN102719401B CN 102719401 B CN102719401 B CN 102719401B CN 201210231840 A CN201210231840 A CN 201210231840A CN 102719401 B CN102719401 B CN 102719401B
- Authority
- CN
- China
- Prior art keywords
- ctl
- cell
- target
- hla
- rhil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012737 microarray-based gene expression Methods 0.000 title claims abstract description 34
- 238000012243 multiplex automated genomic engineering Methods 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 230000000890 antigenic effect Effects 0.000 title claims abstract description 16
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title abstract description 178
- 230000014509 gene expression Effects 0.000 title abstract description 9
- 210000000265 leukocyte Anatomy 0.000 title abstract description 3
- 238000002493 microarray Methods 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 claims abstract description 122
- 238000000034 method Methods 0.000 claims abstract description 69
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 46
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 43
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 42
- 239000000427 antigen Substances 0.000 claims abstract description 33
- 108091007433 antigens Proteins 0.000 claims abstract description 32
- 102000036639 antigens Human genes 0.000 claims abstract description 31
- 239000007790 solid phase Substances 0.000 claims abstract description 11
- 230000004913 activation Effects 0.000 claims abstract description 9
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 5
- 230000003321 amplification Effects 0.000 claims description 61
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 61
- 230000006698 induction Effects 0.000 claims description 21
- 210000002966 serum Anatomy 0.000 claims description 20
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 19
- 239000011324 bead Substances 0.000 claims description 18
- 239000002243 precursor Substances 0.000 claims description 16
- 230000005251 gamma ray Effects 0.000 claims description 15
- 230000009849 deactivation Effects 0.000 claims description 14
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- 230000010261 cell growth Effects 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 230000000638 stimulation Effects 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 238000000684 flow cytometry Methods 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 4
- 230000001464 adherent effect Effects 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000035800 maturation Effects 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 238000005192 partition Methods 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 230000003252 repetitive effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 31
- 108010002350 Interleukin-2 Proteins 0.000 abstract description 28
- 229920001184 polypeptide Polymers 0.000 abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 13
- 230000002147 killing effect Effects 0.000 abstract description 11
- 238000005516 engineering process Methods 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 7
- 238000000926 separation method Methods 0.000 abstract description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 51
- 102000000588 Interleukin-2 Human genes 0.000 description 27
- 210000000612 antigen-presenting cell Anatomy 0.000 description 24
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 102000006354 HLA-DR Antigens Human genes 0.000 description 20
- 108010058597 HLA-DR Antigens Proteins 0.000 description 20
- 102100022297 Integrin alpha-X Human genes 0.000 description 20
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 19
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 15
- 102100033467 L-selectin Human genes 0.000 description 15
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 12
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 102000003812 Interleukin-15 Human genes 0.000 description 9
- 108090000172 Interleukin-15 Proteins 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 8
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 8
- 102100035793 CD83 antigen Human genes 0.000 description 7
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 6
- 101150013553 CD40 gene Proteins 0.000 description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000007791 liquid phase Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- -1 CD86 Proteins 0.000 description 5
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 5
- 108010002586 Interleukin-7 Proteins 0.000 description 5
- 102000000704 Interleukin-7 Human genes 0.000 description 5
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 230000008313 sensitization Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 4
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 231100000225 lethality Toxicity 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000005859 cell recognition Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000017488 activation-induced cell death of T cell Effects 0.000 description 2
- 230000007503 antigenic stimulation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000004719 natural immunity Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000005070 ripening Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010012015 GVYDGREHTV Proteins 0.000 description 1
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100235006 Mus musculus Lctl gene Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
Images
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210231840.XA CN102719401B (zh) | 2012-07-05 | 2012-07-05 | Hla-a0201限制性抗mage抗原特异性ctl的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210231840.XA CN102719401B (zh) | 2012-07-05 | 2012-07-05 | Hla-a0201限制性抗mage抗原特异性ctl的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102719401A CN102719401A (zh) | 2012-10-10 |
CN102719401B true CN102719401B (zh) | 2014-04-23 |
Family
ID=46945274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210231840.XA Active CN102719401B (zh) | 2012-07-05 | 2012-07-05 | Hla-a0201限制性抗mage抗原特异性ctl的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102719401B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749620B (zh) * | 2016-03-29 | 2020-09-25 | 广东香雪精准医疗技术有限公司 | 识别mage-a1抗原短肽的t细胞受体 |
CN106190975A (zh) * | 2016-07-26 | 2016-12-07 | 深圳爱生再生医学科技有限公司 | 黑色素瘤抗原特异性ctl及其制备方法 |
CN108103020A (zh) * | 2018-02-01 | 2018-06-01 | 上海莱馥生命科学技术有限公司 | 一种高效扩增自然杀伤细胞的制备方法 |
CN109536444B (zh) * | 2018-12-11 | 2022-06-28 | 吉林省拓华生物科技有限公司 | 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5433825B2 (ja) * | 2006-08-25 | 2014-03-05 | 株式会社医学生物学研究所 | ウイルス特異的ctlの製造方法 |
-
2012
- 2012-07-05 CN CN201210231840.XA patent/CN102719401B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102719401A (zh) | 2012-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102618498B (zh) | Hla-a0201限制性抗原特异性ctl制备方法 | |
CN103923880B (zh) | 一种高效增殖、靶向杀伤肿瘤的ctl制备方法 | |
AU2006328943B2 (en) | Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer | |
CN102719402B (zh) | Hla-a0201限制性抗hpv抗原特异性ctl的制备方法 | |
JP2019504632A (ja) | Nk細胞培養用培地添加キット、及びキットを用いるnk細胞培養方法 | |
CN102719400B (zh) | Hla-a0201限制性抗cea抗原特异性ctl的制备方法 | |
CN108588022B (zh) | 体外培养富集人cd4+和cd8+ tcm细胞的方法 | |
CN105524884A (zh) | Hla-a0201限制性抗afp抗原特异性ctl的制备方法 | |
CN109161527A (zh) | 一种高效的nk细胞扩增方法 | |
CN102719401B (zh) | Hla-a0201限制性抗mage抗原特异性ctl的制备方法 | |
CN105524883A (zh) | Capri细胞及其制备方法 | |
Aglietta et al. | Ex vivo expansion of hematopoietic cells and their clinical use | |
CN104894072A (zh) | 一种自体自然杀伤细胞增殖的制备方法及其应用 | |
CN112980787B (zh) | 一种特异性杀伤肿瘤细胞的免疫细胞制剂及其制备方法和应用 | |
CN105505871A (zh) | 一种有效扩增cik且提高其特异性杀瘤能力的方法 | |
CN109957543A (zh) | 利用脐带血大量扩增脐血nk细胞的方法 | |
CN103068973A (zh) | 表达Th1特性和溶细胞性质的细胞 | |
CN109535241B (zh) | Dc-cik共培养细胞及其制备方法、致敏抗原和应用 | |
CN105505873A (zh) | HLA-A0201限制性抗Her2-neu抗原特异性CTL的制备方法 | |
US20220177839A1 (en) | Composition, culture medium and method for inducing and/or amplifying tscm in vitro | |
CN113293130B (zh) | 一种肿瘤特异性t细胞的培养方法 | |
CN110628717B (zh) | 一种浸润性t细胞的培养方法 | |
CN105219727A (zh) | 一种用于激活结直肠癌特异性免疫反应的试剂盒 | |
CN105624110A (zh) | Hla-a0201限制性抗psa抗原特异性ctl的制备方法 | |
CN105586312A (zh) | Hla-a0201限制性抗muc-1抗原特异性ctl的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU DECON BIO-SCI-TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SHI HONGZHEN Effective date: 20141024 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 211100 NANJING, JIANGSU PROVINCE TO: 211899 NANJING, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141024 Address after: 211899, Jiangsu Province, Pukou District, Nanjing Pu Road, No. 28, building 1, new mile 5 Patentee after: Jiangsu Kang Biotechnology Co.,Ltd. Address before: Jiangning District of Nanjing City, Jiangsu province 211100 General Road No. 10, Tsinghua Yuan 58 Room 201 Patentee before: Shi Hongzhen |
|
TR01 | Transfer of patent right |
Effective date of registration: 20180917 Address after: 210000 B-6, Jiangsu science and Technology Park, 9 Wei Di Road, Qixia District, Nanjing, Jiangsu. Patentee after: De Kang cell bioengineering Center (Jiangsu) Co.,Ltd. Address before: 210000 room 208, block A, building 10, Spark Road, Pukou District, Nanjing, Jiangsu. Patentee before: Lu Anjun Effective date of registration: 20180917 Address after: 210000 room 208, block A, building 10, Spark Road, Pukou District, Nanjing, Jiangsu. Patentee after: Lu Anjun Address before: 211899 5, building 1, new mileage 28, Tianpu Road, Pukou District, Nanjing, Jiangsu, China Patentee before: Jiangsu Kang Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230111 Address after: Building B6-1, Jiangsu Life Science and Technology Innovation Park, No. 9, Weidi Road, Qixia District, Nanjing, Jiangsu, 210000 Patentee after: Jiangsu Kang Biotechnology Co.,Ltd. Address before: 210000 B-6, Jiangsu science and Technology Park, 9 Wei Di Road, Qixia District, Nanjing, Jiangsu. Patentee before: De Kang cell bioengineering Center (Jiangsu) Co.,Ltd. |
|
TR01 | Transfer of patent right |